Researchers who consider substance utilize have found that ladies who utilize drugs can have issues related to hormones, menstrual cycle, richness, pregnancy, breastfeeding, and menopause. In expansion, ladies themselves depict one of kind reasons for utilizing drugs, counting controlling weight, battling fatigue, adapting with torment, and endeavours to self-treat mental health issues. Womens can react to substances in an unexpected way. For illustration, they may have more sedate longings and may be more likely to backslide after treatment. Sex hormones can make ladies touchier than men to the impacts of a few drugs. Women who utilize drugs may moreover encounter more physical impacts on their heart and blood vessels. Brain changes in ladies who utilize drugs can be diverse from those in men. Women may be more likely to go to the crisis room or pass on from overdose or other impacts of certain substances. Women who are casualties of residential savagery are at expanded hazard of substance utilize.
Separate, misfortune of child care, or the passing of an accomplice or child can trigger women's substance utilize or other mental wellbeing disorders. Women who use certain substances may be more likely to have panic attacks, anxiety, or depression.
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States